26 February 2015 - PHARMAC is seeking feedback on a provisional agreement with Janssen-Cilag Pty Ltd. In summary, this proposal is, from 1 May 2015, to:

• Fund abiraterone acetate (Zytiga) 250 mg tablets for patients with metastatic castration resistant prostate cancer;
• List two additional presentations of epoetin alfa (Eprex) – Inj 8,000 iu in 0.8 ml syringe and Inj 40,000 iu in 1 ml syringe; and
• Reduce the net cost of methylphenidate hydrochloride extended-release tablets (Concerta) and topiramate tablets and sprinkle capsules (Topamax).

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-02-26-various/